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Background: Bone morphogenic proteins 4 (BMP4) is associated with cardiac remodeling under different
conditions. However, the role of BMP4 and its gene polymorphism in the incidence of left ventricular hypertrophy
(LVH) in hypertensive patients remains unknown.
Methods: A total of 1265 patients diagnosed with essential hypertension (EH) were recruited. Patients were
assigned to LVH+ (n = 420) and LVH- (n = 845) groups. serum BMP4 level was measured and two single nucleotide
polymorphism (SNPs) polymorphisms, 6007C > T and -5826G > A of BMP4 gene were genotyped. We also inhibited
the BMP4 by small interfering RNA (siRNA). The effect of BMP4 on the hypertrophic response in Human Cardiomyocytes
AC16 cells was studied.
Results: We found that the 6007C > T polymorphism of the BMP4 gene and the serum BMP4 level were significantly
associated with the risk to develop LVH. With TT as reference, multivariate logistic regression analysis showed the
6007CC genotype carriers had a higher susceptibility to LVH incidence (adjusted OR = 2.65, 95% CI: 1.63-4.31,
adjusted P < 0.001). Our in vitro study shows that the BMP4 inhibition in cardiomyocyte by si-RNA technique significantly
decreased the Ang II induced cardiomyocyte size and protein content per cell, indicating the importance of BMP4 in
the cardiomyocyte hypertrophy.
Conclusion: Collectively, our data suggest that both the 6007C > T of the BMP4 gene and the serum BMP4 level may
be used as potential marker for LVH incidence among the EH patients.
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Left ventricular hypertrophy (LVH) is one of the major
complication of high blood pressure, which is regarded
as an independent risk factor for cardiovascular morbidity
and mortality [1-4]. The established risk factors responsible
for LVH includes blood pressure level, duration of hyper-
tension, age, obesity, diet, and pharmacologic treatment
[5,6]. In addition, a large body of evidence shows that the
individual genetic background predisposes the LVH inci-
dence [7-9]. Identifying the key factor mediating patho-
logical cardiac hypertrophy is critically important for
developing the strategy to protect against heart failure.* Correspondence: sh_gugl@126.com
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unless otherwise stated.BMP4 is a member of bone morphogenic proteins
(BMP) superfamily, regulating osteoblast differentiation
and bone formation [10-13]. In addition, BMP4 is a
mechanosensitive and proinflammatory gene, and it in-
duces endothelial cell apoptosis, and endothelium dysfunc-
tion [14,15]. BMP4 induces cardiomyocyte differentiation
and promotes cardiomyocyte apoptosis after ischemia-
reperfusion injury–induced myocardial infarction [16,17].
The association between BMP4 and cardiac remodeling is
recently reported. BMP4 is expressed in human and mouse
hearts and recombinant BMP4 protects adult mouse car-
diomyocytes against hypoxia-reoxygenation injury [18].
BMP4 induces cardiomyocyte hypertrophy and apoptosis
through increasing nadph oxidase 4 expression and react-
ive oxygen species-dependent pathways [19].s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cleotide polymorphisms (SNPs), may result in a qualitative
or quantitative change in the local production of BMP4 or
in its effectiveness via its cognate receptor [20]. Although
many mutations within BMP4 leading to various pheno-
types have been reported [21], the single nucleotide poly-
morphism of 6007C > T (rs17563) of BMP4 is the only
identified polymorphism in the coding region [22]. To
date, there is no study regarding the association between
BMP4 gene polymorphism and LVH incidence.
Given the association between BMP4 and cardiac re-
modeling [19], we postulate that the BMP4 gene poly-
morphism may also affect the cardiac remodeling. In
this study, we enrolled essential hypertentive patients
with and without LVH, to test this hypothesis.
Methods
Enrollment
A total of 1265 patients diagnosed with EH were recruited
in our hospital from July 2007 to March 2012. All patients
were assigned into LVH+ (EH with LVH) and LVH- (EH
without LVH) groups based on the presence or absence
of LVH. A complete medical history was obtained from
all subjects, including diabetes mellitus (DM), alcohol
intake, cigarette smoking, weight, height, body mass
index (BMI), systolic blood pressure (SBP), and diastolic
blood pressure (DBP). The study protocol was approved
by the ethics committee of Nanjing University of Chin-
ese Medicine. All patients provided an informed written
consent. We measured total cholesterol (TC), total trigly-
ceride (TG), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), creatine kinase
(CK), creatine kinase-MB (CK-MB), troponin T (TNT),
fasting blood glucose (FBG), blood urea nitrogen (BUN),
and serum creatinine [23].
Measurement of LVH
The echocardiography was performed in three cardiac
cycles at end diastole and end systole, by the two investi-
gators who were blind to the genotypes of the patients
using a Hewlett–Packard imaging system (Sonos 2500
model, California). All measurements LV mass (LVM)
was calculated at end-diastole using the formula: 0.8 ×
1.04[(IVSd + LVIDD + PWTd) − LVIDD] + 0.6 (IVSd: in-
terventricular septal thickness, PWTd: posterior wall
thickness, LVIDD: LV end-diastolic internal dimension),
which yields values closely related (R = 0.90) to necropsy
LV weight. LVM was divided by height 2.7 to obtain LVMI
(LVM index). LVH was defined as LVMI > 49.2 g/2.7 m
for men and >46.7 g/2.7 m for women [13].
Genotyping of BMP4 gene
DNA was extracted from peripheral whole blood using a
Qiagen DNA Isolation Kit (Qiagen, Valencia, CA, USA).The specific product of the BMP4 gene was amplified by
polymerase chain reaction (PCR) with primers 5’-biotion-
TGAAGGCAAGATGTCTGA- CACA-3’ (forward) and
5’-CCTTCCTGCATTTCTATCCTA-3’ (reverse) for -5826
G>A (rs1957860), and 5’-ATTGCCCAACCCTGAGCT
ATC-3’ (forward) and 5’-biotin-TGGGGGCTTCATAACC
TC-3’ (reverse) for 6007C > T (rs17563). Reactions were
performed in a total volume of 20 μl. The thermocycling
procedure consisted of initial denaturation at 95°C for
3 minutes, 35 cycles of denaturation at 94°C for 30 sec-
onds, annealing at 60°C for 40 seconds, extension at 72°C
for 1 minute and a final extension at 72°C for 10 minutes.
The PCR products were analyzed by electrophoresis on
1% agarose gel [24].
Serum BMP4 and other cytokine Measurement
Serum BMP4 was measured using the BMP4 Duoset enzyme
linked immunoassay kit (R & D Systems, Minneapolis, MN)
according to manufacturer’s instructions. Samples were
assayed in duplicate. The interassay coefficient of variance
was < 14% and the detection limit of the assay was
15.6 pg/mL [25]. Serum cystatin-C was measured using
an immunoturbidimetric method (Roche Diagnostics,
Indianapolis, IN) following the manufacturer’s recommen-
dations. The PIIINP levels were assayed using enzyme
linked immunosorbent assay kits (Nivelles, Belgium). The
Serum hs-CRP level was measured by using the high sensi-
tivity CRP Vario assay (Abbott Laboratories, Abbott Park,
Illinois).
Rat cardiomyocytes culture
The whole hearts from neonate rats were isolated, minced
and rinsed in hood by using by using a device invented by
Xuwei Hou (patent number: CN 101955884 A and CN
101955884 B). Briefly, whole hearts from neonate rats (age
less than 3 days) were isolated, minced and rinsed in hood.
Five to six cycles of digestion using collagenase (95 U/ml,
Sigma Aldrich, Bornem, Belgium) and 0.6 U/ml of pan-
creatin (Sigma Aldrich, Bornem, Belgium) were per-
formed. After cell plating on non-coated culture dishes for
2 h to allow differential attachment of non-myocyte cells,
the remaining cell suspension containing neonatal cardio-
myocytes was collected, counted, and seeded at 5*104
cells/cm2 in collagen I-coated culture dishes. The medium
was replaced after 72 h and cardiomyocytes were allowed
to reach confluence before use. The isolated cardiomyo-
cytes were pooled and resuspended in mixed medium
containing DMEM and M199 (volume ratio: 4:1) and 10%
fetal bovine serum (FBS) in incubator at37 degree with 5%
CO2 [26].
BMP4 siRNA transfection
Cultured cells were expanded to reach a 70% confluence.
Then cells were maintained in antibiotic free mixed
Table 1 Clinical and biochemical characteristics of all
subjects
Variables LVH+ N = 420 LVH− N = 845 P value
Age (years) 52.5 ± 6.6 51.8 ± 8.4 NS
Male (n, %) 67.5% 68.2% NS
Alcohol intake (n, %) 32.8% 30.5% NS
Smoker (n, %) 46.7% 26.4.1% 0.011
BMI (kg/m2) 24.4 ± 2.2 23.8 ± 3.5 NS
SBP (mmHg) 152.9 ± 8.0 149.6 ± 11.5 NS
DBP (mmHg) 87.8 ± 7.9 89.5 ± 10.6 NS
TG (ng/dl) 5.2 ± 2.8 5.1 ± 2.3 NS
TC (ng/dl) 1.6 ± 0.3 1.6 ± 0.4 NS
HDL-C (ng/dl) 1.3 ± 0.8 1.7 ± 0.5 NS
LDL-C (ng/dl) 2.5 ± 0.8 2.6 ± 0.5 NS
sCr (mmol/l) 101.6 ± 11.5 90.8 ± 12.7 NS
Duration since
EH diagnosis (months)
24.4 ± 3.9 23.7 ± 5.2 NS
Therapy protocol
ACEI (%) 36.7 35.9 NS
Time (month) 17.7 ± 3.2 16.8 ± 4.8 NS
ARB (%) 28.9 28.9 NS
Time (month) 12.8 ± 2.2 12.4 ± 1.8 NS
CCB (%) 33.2 32.6 NS
Time (month) 13.5 ± 3.1 13.4 ± 1.9 NS
Diuretics (%) 6.8 6.7 NS
Time (month) 8.7 ± 2.1 8.8 ± 2.6 NS
β-blocker (%) 23.7 24.1 NS
Time (month) 16.2 ± 3.0 16.0 ± 2.3 NS
Others (%) 22.7 21.8 NS
Time (month) 7.7 ± 1.2 7.8 ± 0.9 NS
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fore si-RNA transfection. Nonspecific control siRNA
or BMP4 siRNA (Santa Cruz Biotechnology, USA) was
transfected by siLentFect Lipid Reagent (Bio-Rad,
Hercules, CA, USA) for 48 hours in an incubator at 37
degree with 5% CO2, according to the manufacturer’s
instructions.
Hypertrophy assays
Cardiomyocytes were stimulated with 10(−6) mol/L
angiotensin (Ang) II for 48 h. Then the cells were fixed
in 4% paraformaldehyde, stained with FITC-conjugated
Phalloidin (Sigma) for 30 min and mounted in Vectashield
with 4’,6-diamidino-2-phenylindole (Vector Laboratories,
Peterborough, UK). Cellular hypertrophy was evaluated by
measuring cardiomyocytes and cardiac fibroblasts surfaces
using a digital image analysis system (Leica QwinV3, Leica
Microsystems Ltd., Cambridge, UK). Five random fields
(with approximately 10 to 15 cells per field) from every
sample were averaged and expressed as μm2/cell. All
experiments were repeated three times.
Measurement of Protein Synthesis in cardiomyocytes
The AngII treated cells were trypsinized and counted
using a cell counting chamber (Beckman Coulter, Fullerton,
CA, USA) and then lysed. A total of 1*10(5) cells were
used for the Protein Synthesis measurement. The cell
lysates were prepared to determine protein content by
Bradford protein assay. Then the protein synthesis of cells
was determined by dividing the total amount of protein by
the number of cells, namely, protein per cell [27].
Statistical analysis
Data on quantitative characteristics are expressed as
means ± SD. Data on qualitative characteristics are expressed
as percent values or absolute numbers, as indicated. Dif-
ferences in demographic characteristics and vascular risk
factors between patients and controls were compared by
using Student’s t test for continuous variables and the χ2
test for all categorical variables. Tests for Hardy-Weinberg
equilibrium for the gene polymorphisms were conducted
using χ2 tests. Genotypes and allele frequencies were
compared by χ2 analysis. Multivariate logistic regression
analysis was used to determine the influence of BMP4
polymorphisms on LVH risk, with controlling potential
confounding risk variables. A forward stepwise (Likeli-
hood Ratio) procedure was used for multivariable analysis.
Data were analyzed with the SPSS 13.0 package (SPSS Inc)
and results were considered statistically significant at
P < 0.01 using a 2-tailed test.
Results
The clinical and biochemical characteristics of all sub-
jects are shown in Table 1. A total of 420 patients wereassigned to the LVH+ group and 845 to the LVH- group.
There were no significant differences in age, sex, alcohol
intake, BMI, TG, TC, HDL, LDL and sCr between LVH+
and LVH- groups. In addition, the treatment time of
ACEI/ARBs was similar between two groups. The mean
LVMI in LVH+ group was 51.3 ± 3.8 g/m2 while that in
LVH− group was 43.3 ± 4.1 g/m2 (P < 0.001, Table 1).
Genotype frequencies of BMP4 polymorphisms in
LVH+ (N = 420) and LVH- (N = 845) groups were found
to be in Hardy–Weinberg equilibrium (all P > 0.05). The
genotype and the allele frequencies of -5826G > A were
not significantly different between two groups. However,
the genotypes and allele frequency of 6007C > T were
significantly different between LVH+ and LVH- patients.
The 6007CC genotype was much more prevalent in
LVH+ patients than LVH- patients (33.10%% vs. 19.17%,
Table 2). With TT as reference, multivariate logistic re-
gression analysis showed the 6007CC genotype carriers
Table 2 The genotype frequencies for BMP-4 polymorphisms between LVH+ and LVH- groups
LVH+ LVH- Adjusted OR 95% CI Adjusted P
−5826G > A N = 420 N = 845 %
6007C > T TT 90 21.43% 243 28.76% 1.00
CT 191 45.48% 436 51.60% 1.18 0.88 1.59 0.265 0.259
CC 139 33.10% 166 19.64% 2.26 1.62 3.15 0.000 0.000
T 371 44.17% 922 54.56% 1.00
C 469 55.83% 768 45.44% 1.52 1.28 1.79 0.000 0.000
6007C > T −5826G > A TT 107 25.48% 201 23.79% 1.00
CT 205 48.81% 437 51.72% 0.88 0.66 1.17 0.388 0.542
CC 108 25.71% 207 24.50% 0.98 0.70 1.36 0.905 0.524
T 419 49.88% 839 49.64% 1.00
C 421 50.12% 851 50.36% 0.99 0.84 1.17 0.911 0.517
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OR = 2.33, 95% CI: 1.67-3.25, adjusted P < 0.001) with
adjustment for age, sex, smoke status, TG, TC, BP level,
serum hs-CRP, serum OPN levels. The 6007C allele
conferred a higher risk for LVH development (adjusted
OR = 1.54, 95% CI: 1.30-1.82, P < 0.001) compared with
T allele carriage.
We next analyzed the association between the BMP4
genotype and the serum BMP4 levels. We found that the
6007C > T significantly affect the serum BMP4 level
(Figure 1A). The 6007CC genotype carries had higher serum
BMP4 levels than CT and TT carriers (P < 0.001). Moreover,
the 6007C > T is also significantly associated with the
serum cystatin C, PIIINP and hs-CRP levels (Figure 1B-D,
all P < 0.001). In contrast, the -5826G > A genotype did
not affect the serum BMP4, cystatin C, PIIINP and hs-CRP
levels.Figure 1 The association between the BMP4 genotype and the serum
carries had higher serum BMP4 levels than CT and TT carriers (A). Moreove
C (B), PIIINP (C) and hs-CRP (D) levels (Figure B-D, all P < 0.001).We next investigated the correlation between serum
BMP4, serum cystatin C and serum hs-CRP levels with
the LVMI in patients. We observed a significantly
correlation between serum BMP4 and LVMI (r = 0.534,
P < 0.001). Likewise, the serum cystatin C and PIIINP
levels are also correlated to the LVMI (r = 0.542, P = 0.002;
r = 0.688, P < 0.001respectively). No correlation was found
between serum hsCRP and LVMI in this study (r = 0.162,
P = 0.061). The serum BMP4 level was significantly
correlated to the serum cystatin C, and PIIINP (r = 0.421,
P = 0.002; r = 0.582, P < 0.001, respectively).
In the in vitro study, the BMP4 inhibition by si-RNA
was confirmed by western blot assay (Figure 2). BMP4
si-RNA transfection dramatically inhibited the BMP4 ex-
pression compared to the control si-RNA.
AngII dramatically increased the cellular surface in
cardiomyoctye transfected with control siRNA. However,BMP4, cystatin C, PIIINP and hs-CRP levels. The 6007CC genotype
r, the 6007C > T is also significantly associated with the serum cystatin
Figure 2 The BMP4 expression in cardiomyocytes after si-RNA
transfection. BMP4 si-RNA transfection dramatically inhibited the
BMP4 expression compared to the control si-RNA.
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face was markedly smaller than that in control si-RNA
transfected cells (560 ± 78 vs. 223 ± 78 um2/cell, P < 0.001,
Figure 3A) Similarly, the cellular protein synthesis dramat-
ically decreased by BMP4 si-RNA transfection compared
to control si-RNA transfection (1.3 ± 0.2 vs. 0.5 ± 0.2 ng/cell,
P < 0.001, Figure 3B).
Discussion
In the present study, we explored the correlations of the
BMP4 gene polymorphisms and the serum BMP4 levels
with the development of LVH among Chinese EH pa-
tients. We found that the 6007C > T polymorphism of
the BMP4 gene and the serum BMP4 level were signifi-
cantly associated with the risk to develop LVH. Our
in vitro study shows that the BMP4 inhibition in cardio-
myocyte by si-RNA technique significantly decreased the
Ang II induced cardiomyocyte size and protein content
per cell, indicating the importance of BMP4 in the cardio-
myocyte hypertrophy. Collectively, our data suggest that
both the 6007C > T of the BMP4 gene and the serum
BMP4 level may be used as potential marker for LVH inci-
dence among the EH patients.
Bone morphogenetic proteins are osteoinductive growth
factors that play a key role in cell differentiation, prolifera-
tion, migration, development, and apoptosis. BMP4 has
been linked to the receptor-activator of nuclear factor-κBFigure 3 BMP4 si-RNA transfection on the AngII induced cellular surfa
dramatically increased the cellular surface in cardiomyoctye transfected wit
cellular surface was markedly smaller than that in control si-RNA transfected
by BMP4 si-RNA transfection compared to control si-RNA transfection (B).ligand (RANKL) mediated calcification in vessel smooth
muscle cells [21]. Additional reports suggest roles for
BMP4 in endothelial cell dysfunction, inflammation, and
hypertension [15,22,28].
Several studies about BMP4 in cardiovascular system
have implied that BMP4 might be involved in pathological
cardiac hypertrophy, for example, BMP4 stimulates ROS
production through NADPH oxidases in endothelium, ex-
aggerates cardiac ischemia-reperfusion injury by promot-
ing cardiomyocytes apoptosis [17]. BMP4 was involved in
valvular interstitial cell activation in human myxomatous
mitral valve prolapse [29]. BMP4 induces cardiomyocyte
hypertrophy and apoptosis through increasing nadph oxi-
dase 4 expression and reactive oxygen species-dependent
pathways [19]. BMP4 is expressed in pathological cardiac
hypertrophy models and BMP4-mediated cardiomyocyte
hypertrophy [30]. In this study, we found that the BMP4
inhibition by si-RNA technique significantly blunt the
AngII induced the hypertrophy of cardiomyocyte in vivo,
supporting the role of BMP4 in the regulation of hyper-
trophic response of cardiomyocytes.
The single nucleotide polymorphism of 6007C > T
(rs17563) of BMP4 is the only identified polymorphism
in the coding region [31]. The 6007 C > T polymorphism
results in an amino acid change from valine to alanine at
residue 152 (p.Val152Ala), thus affects the BMP4 gene
expression. The T-allele was predicted to change mRNA
structure and the BMP4 mRNA levels were significantly
higher in T-allele carriers compared with C-allele car-
riers, even the BMP4 protein plasma levels were higher
among T-allele carries, but without reaching the statis-
tical significance [32]. A recent study A significant asso-
ciation was observed between the 455C allele of BMP4
and increased left ventricular internal diameter systolic
(p = 0.004) and between 1650 T allele of BMPR1B and
lower left atrium diameter (p = 0.038). Presence of the
455C allele of BMP4 and the 8474 T allele of ACVR1
gene was significantly associated with decreased left ven-
tricular ejection fraction (LVEF) (p = 0.0004 and p = 0.046,
respectively). The 455C allele of BMP4 plays a role asce and cellular protein synthesis in cardiomyoctyes. AngII
h control siRNA. However, in cells transfected with BMP4 si-RNA, the
cells (A) Similarly, the cellular protein synthesis dramatically decreased
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in newborns [33]. In this study, we found that the single
nucleotide polymorphism of 6007C > T is significantly
associated with the incidence of LVH in hypertensive
patients, suggesting this genetic polymorphism can be
used as molecular marker for LVH development. To the
best of our knowledge, this is the first study reporting
the role of BMP4 genetic polymorphism with the LVH.
We studied several well established cytokine makers
for prediction of LVH including cystatin C, PIIINP and
hr-CRP. Serum cystatin C levels can be used to predict
morbidity and mortality in patients with cardiovascular
disease. A recent study shows that Serum cystatin C
levels were higher in hypertensive patients with LVH
than in those without LVH [34,35]. A community-based
prospective cohort study reveals that serum PIIINP
levels were higher in the presence of LVH than with no
LVH in in hypertensive patients [36]. An independent risk
factor for left ventricular hypertrophy in patients with
lupus nephritis [37]. A positive association of left ventricu-
lar hypertrophy with high-sensitive CRP in hemodialysis
patients has been reported [38]. In our study, we found
that the 6007CC genotype carries had higher serum
BMP4, cystatin C, PIIINP and hs-CRP levels. Correl-
ation analyses reveal serum BMP4 level was significantly
correlated to the serum cystatin C and PIIINP. We did
not observed a positive correlation between hs-CRP and
LVH in hypertensive patients in our study.
Several limitations should be addressed in this study.
First, this is a single center based study and all the par-
ticipants were ethnically Chinese in southeastern China
area. Secondly, the sample size is relatively small. Secondly,
we did not perform the functional role of BMP4 6007C >T
mutation in cardiomyocytes due to the unavailability of
BMP4 mutation plasmid.
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